Syros Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
OTC.Pink
Point72 Asset Management, along with its affiliates and Steven A. Cohen, has filed an amended Schedule 13G disclosing a 0.0% beneficial ownership stake in Syros Pharmaceuticals, Inc. as of December 31, 2024.
OTC.Pink
Avidity Partners Management LP and its affiliated entities have filed an amended Schedule 13G, disclosing a continued passive beneficial ownership of 7.6% in Syros Pharmaceuticals, Inc. as of December 31, 2024.
OTC.Pink
Deep Track Capital, along with its affiliated entities, has filed an amended Schedule 13G indicating a complete divestment of their beneficial ownership in Syros Pharmaceuticals, Inc.
OTC.Pink
Invus Public Equities, L.P. and its affiliated entities have reported a reduction in their beneficial ownership of Syros Pharmaceuticals, Inc. common stock to 3.8%, falling below the 5% threshold.
OTC.Pink
Adage Capital Management, L.P. and its affiliates have reported a 1.98% beneficial ownership stake in Syros Pharmaceuticals, Inc. as of December 31, 2024, held for investment purposes.